A341170 Stock Overview
Future Medicine Co., Ltd. operates as a drug development company worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Future Medicine Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩3,870.00 |
52 Week High | ₩9,250.00 |
52 Week Low | ₩3,030.00 |
Beta | 0 |
1 Month Change | -35.39% |
3 Month Change | -39.44% |
1 Year Change | -35.93% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -60.10% |
Recent News & Updates
Recent updates
Shareholder Returns
A341170 | KR Pharmaceuticals | KR Market | |
---|---|---|---|
7D | -0.8% | 1.5% | 2.7% |
1Y | -35.9% | 9.1% | 5.8% |
Return vs Industry: A341170 underperformed the KR Pharmaceuticals industry which returned 9.1% over the past year.
Return vs Market: A341170 underperformed the KR Market which returned 5.8% over the past year.
Price Volatility
A341170 volatility | |
---|---|
A341170 Average Weekly Movement | 10.5% |
Pharmaceuticals Industry Average Movement | 4.5% |
Market Average Movement | 5.1% |
10% most volatile stocks in KR Market | 11.7% |
10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A341170's share price has been volatile over the past 3 months.
Volatility Over Time: A341170's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2015 | n/a | Shin Jeong Lak | www.futuremedicine.co.kr |
Future Medicine Co., Ltd. operates as a drug development company worldwide. It develops drugs for use in the treatment of fibrosis and inflammation in non-alcoholic steatohepatitis, chronic kidney disease, glaucoma, and primary biliary cirrhosis; colorectal, prostate, and lung cancer; and COVID-19 and rheumatoid arthritis/atopy. The company was founded in 2015 and is based in Seongnam, South Korea.
Future Medicine Co., Ltd. Fundamentals Summary
A341170 fundamental statistics | |
---|---|
Market cap | ₩35.90b |
Earnings (TTM) | ₩0 |
Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs A341170 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A341170 income statement (TTM) | |
---|---|
Revenue | ₩0 |
Cost of Revenue | ₩0 |
Gross Profit | ₩0 |
Other Expenses | ₩0 |
Earnings | ₩0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
Earnings per share (EPS) | 0 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.0% |
How did A341170 perform over the long term?
See historical performance and comparison